Daliresp

Roflumilast (Daliresp®, Daxas®) is a selective phosphodiesterase 4 (PDE4) inhibitor that decreases systemic and pulmonary… Expand

Roflumilast therapy has a limited role in patients with severe COPD, and no role in patients with mild to moderate COPD. It will… Expand

Objective To identify the structure of the new drug daliresp. Methods The structure of daliresp w as identified by UV,IR,MS,1H… Expand

APIXABAN (ELIQUIS®) FOR ORAL ANTICOAGULATION IN NONVALVULAR ATRIAL FIBRILLATION hronic obstructive pulmonary disease (COPD) is a… Expand

PURPOSE The pharmacology, pharmacokinetics, efficacy, and safety of roflumilast-the first in a new class of agents for managing… Expand

Chronic obstructive pulmonary disease (COPD) is characterized by a gradual and progressive loss of lung function. The consensus… Expand

is substantial. Quality of life, morbidity, and mortality are all negatively affected by the disease. In the National Health and… Expand

 

Roflumilast (Daxas® [EU], Daliresp® [USA]) is the first phosphodiesterase 4 inhibitor approved in Europe to be used in severe… Expand

roflumilast Chronic obstructive pulmonary disease (COPD) is a progressive, irreversible lung disease that is often associated… Expand